T. Fukuyama et al. / Journal of Organometallic Chemistry 692 (2007) 685–690
689
4.5. Determination of solubility of ionic liquids to organic
solvents
24.49, 25.48, 26.42, 27.08, 29.33, 31.40, 31.75, 42.45,
42.88, 46.84, 166.20, 204.60; IR (neat) 1447 cmꢀ1
,
1641 cmꢀ1, 1709 cmꢀ1; MS (relative intensity) m/z 253
(M+, 15), 113 (29), 112 (100), 71 (66), 69 (89), 57 (73);
HRMS (EI) calc. for C15H27NO2 m/z 253.2042, found:
253.2034.
A mixture of [bmim]NTf2 (895.4 mg) and ether (5 mL)
was vigorously stirred at room temperature for 5 min.
After standing for 5 min, the ether layer was decanted. This
was repeated an additional two times. The combined ether
layer was evaporated and the residue weighed to give
56.6 mg (6.3 wt%) of [bmim]NTf2.
4.10. N,N-diethyl-2-butylhexanamide (4e)
1H NMR (CDCl3, 500 MHz) d 3.41–3.32 (m, 4H),
2.53–2.48 (m, 1H), 1.65–1.58 (m, 3H), 1.46–1.39 (m,
2H), 1.32–1.20 (m, 10H), 1.18 (t, J = 7.1 Hz, 3H), 1.11
(t, J = 7.1 Hz, 3H), 0.88 (t, J = 7.1 Hz, 3H); 13C NMR
(CDCl3, 125 MHz) d 13.09, 13.97, 14.00, 14.91, 22.99,
29.94, 33.07, 40.37, 41.32, 41.83, 175.60; IR (neat)
1460 cmꢀ1, 1638 cmꢀ1; MS (relative intensity) m/z 227
(M+, 2), 184 (23), 171 (50), 128 (30), 128 (100), 115
(49), 100 (53), 73 (34), 71 (45), 58 (66), 57 (37), 44 (48),
43 (64), 41 (49); HRMS (EI) calc. for C14H29NO m/z
227.2249, found: 227.2235.
4.6. N-hexyl-3-methyl-2-oxononanamide (5b)
1H NMR (CDCl3, 500 MHz) d 6.94 (s, 1H), 3.98–3.53
(m, 1H), 3.29 (q, J = 6.7 Hz, 2H), 1.67 (m, 1H), 1.56–
1.51 (m, 3H), 1.34–1.25 (m, 16H), 1.10 (d, J = 6.9 Hz,
3H), 0.90–0.86 (m, 6H); 13C NMR (CDCl3, 125 MHz) d
14.05, 14.13, 15.68, 15.71, 22.58, 22.64, 26.59, 27.18,
29.30, 31.45, 31.72, 32.56, 38.91, 39.44, 160.03, 202.71; IR
(neat) 1461 cmꢀ1, 1677 cmꢀ1, 1716 cmꢀ1, 3330 cmꢀ1; MS
(relative intensity) m/z 269 (M+, 7), 85 (26), 81 (22), 71
(71), 57 (100), 55 (44); HRMS (EI) calc. for C16H31NO2
m/z 269.2355, found: 269.2357.
4.11. N,N-diethyl-2-methyl-4-phenylbutylamide (4f)
4.7. N-benzyl-3-methyl-2-oxononanamide (5c)
1H NMR (CDCl3, 500 MHz) d 7.27–7.26 (m, 3H), 7.18
(d, J = 7.8 Hz, 2H), 3.47–3.40 (m, 2H), 3.35–3.24 (m,
2H), 3.28–3.14 (m, 2H), 2.60–2.55 (m, 1H), 2.07–2.00 (m,
1H), 1.74–1.07 (m, 1H), 1.14 (d, J = 6.4 Hz, 3H), 1.12 (t,
J = 7.1 Hz, 3H), 1.07 (t, J = 7.3 Hz, 3H); 13C NMR
(CDCl3, 125 MHz) d 13.21, 14.89, 33.62, 34.79, 35.98,
40.43, 128.37, 128.41, 128.45, 142.07, 175.57; IR (neat)
1454 cmꢀ1, 1939 cmꢀ1; MS (relative intensity) m/z 233
(M+, 1), 129 (100), 114 (25), 91 (55), 72 (24), 58 (34), 44
(28); HRMS (EI) calc. for C15H23NO m/z 233.1780, found:
233.1779.
1H NMR (CDCl3, 500 MHz) d 7.42–7.24 (m, 5H), 4.49
(s, 2H), 1.73–1.68 (m, 1H), 1.56 (s, 1H), 1.35–1.26 (m,
9H), 1.12 (d, J = 5.9 Hz, 3H), 0.88 (t, J = 6.6 Hz, 3H);
13C NMR (CDCl3, 125 MHz) d 14.15, 15.71, 22.66,
27.20, 29.34, 31.74, 32.57, 39.12, 43.52, 127.93, 128.91,
159.94, 202.36; IR (neat) 1455 cmꢀ1
,
1679 cmꢀ1
,
1716 cmꢀ1, 3340 cmꢀ1; MS (relative intensity) m/z 275
(M+, 2), 141 (27), 91 (100), 71 (74), 57 (79); HRMS
(EI) calc. for C17H25NO2 m/z 275.1885, found: 275.1879.
4.8. 1-(2-Methyl-1-oxooctyl)piperidine (4d)
4.12. N, N-diethyl-2-methyl-4-phenylsulfanylbutylamide
(4g)
1H NMR (CDCl3, 500 MHz) d 3.63-3.41 (m, 4H), 2.68
(sext, J = 6.8 Hz, 1H), 1.69–1.64 (m, 3H), 1.57–1.52 (m,
4H), 1.37–1.26 (m, 9H), 1.09 (d, J = 6.9 Hz, 3H), 0.87
(t, J = 6.6 Hz, 3H); 13C NMR (CDCl3, 125 MHz) d
14.12, 17.71, 22.68, 24.79, 25.82, 26.89, 27.53, 29.46,
31.83, 34.22, 35.26, 42.88, 46.62, 175.00; IR (neat)
1434 cmꢀ1, 1643 cmꢀ1; MS (relative intensity) m/z 225
(M+, 8), 154 (62), 142 (31), 141 (100), 140 (36), 112
(66), 86 (35), 85 (71), 84 (77), 71 (32), 70 (33), 69 (70),
57 (26), 56 (45), 55 (30), 44 (40), 43 (70), 42 (55), 41
(82); HRMS (EI) calc. for C14H27NO m/z 225.2093,
found: 225.2081.
1H NMR (CDCl3, 500 MHz) d 7.31 (t, J = 8.0 Hz, 2H),
7.27 (d, J = 6.4 Hz, 1H), 7.10 (t, J = 7.3 Hz, 2H), 3.41–3.25
(m, 4H), 3.02–2.97 (m, 1H), 2.92–2.81 (m, 2H), 2.11 (sext,
J = 7.0 Hz, 1H), 1.69 (sext, J = 6.8 Hz, 1H), 1.18 (t,
J = 7.1 Hz, 3H), 1.13–1.08 (m, 6H); 13C NMR (CDCl3,
125 MHz) d 13.21, 15.02, 18.05, 31.40, 33.32, 34.20,
40.47, 41.97, 125.84, 128.95, 128.97, 136.47, 175.00; IR
(neat) 1439 cmꢀ1, 1635 cmꢀ1; MS (relative intensity) m/z
265 (M+, 43), 156 (74), 129 (100), 123 (28), 100 (35);
HRMS (EI) calc. for C15H23NOS m/z 265.1500, found:
265.1506.
4.9. 1-(3-Methyl-1,2-dioxononyl)piperidine (5d)
4.13. N-benzyl-N-ethyl-2,2-dimethylpropionamide (4j)
1H NMR (CDCl3, 500 MHz) d 3.58 (t, J = 5.5 Hz,
2H), 3.31 (t, J = 5.5 Hz, 2H), 3.08 (sext, J = 6.7 Hz,
1H), 1.77–1.66 (m, 2H), 1.64–1.57 (m, 5H), 1.36–1.28
(m, 9H), 1.12 (d, J = 6.9 Hz, 3H), 0.88 (t, J = 6.9 Hz,
3H); 13C NMR (CDCl3, 125 MHz) d 14.13, 14.57, 22.66,
1H NMR (CDCl3, 500 MHz) d 7.32 (t, J = 7.6 Hz, 2H),
7.26–7.24 (m, 1H), 7.19 (d, J = 6.9 Hz, 2H), 4.66 (s, 2H),
3.38 (s, 2H), 1.38 (s, 9H), 1.13–1.11 (m, 3H); 13C NMR
(CDCl3, 125 MHz) d 28.71, 28.74, 39.16, 41.69, 127.15,